Oric Pharmaceuticals initiated with an Overweight at Piper Sandler

Piper Sandler analyst Kelsey Goodwin initiated coverage of Oric Pharmaceuticals (ORIC) with an Overweight rating and $22 price target The company’s ORIC-944 is a potential best-in-class PRC2 inhibitor capable of becoming a standard of care treatment class in prostate cancer, the analyst tells investors in a research note. Piper believes the ORIC-944 clinical update in Q1 “is likely to represent a value creation event.”